Drugs / TriMix
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02413645 | Jun 2015 → Jun 2016 | HIV infectious disease | Judit Pich Martínez | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02888756 | Apr 2017 → Feb 2018 | HIV infectious disease | Rob Gruters | Terminated | Missed primary |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06478134 | Jul 2023 → Jan 2024 | dry eye syndrome | University of Seville | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT03788083 Comparator | Nov 2018 → Sep 2024 | female breast carcinoma | University Hospital Brussels | Unknown | No outcome recorded |
| Phase 2/3 | NCT04172558 Comparator | Mar 2019 → Oct 2022 | erectile dysfunction | Benha University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trimix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04172558 ↗ |
| Modality | Messenger RNA (mRNA) | “100 μg of mRNA (i.e. 100 μg TriMix mRNA)” NCT02413645 ↗ |
| Route | Other | “three intranodal doses of mRNA” PMID 30289805 ↗ Nov 2018 |